Exec Tells DAILY: Shire Wants FDA Meeting Before Phase III Fosrenol Trial in Pre-Dialysis CKD Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Results from Phase II study could put Genzyme’s competing Renvela at an advantage, though Shire used a more aggressive endpoint.
You may also be interested in...
Advisory Committee Rejects Surrogate Endpoint For Phosphate Binders
Sponsors are seeking to expand the indication of the CKD therapies without clinical data.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.